Safety study of inhaled treprostinil in people with liver disease
Treatments studied
This early-stage study tests how the body processes a new inhaled breathing medication (treprostinil) and whether it's safe in people with normal liver function and those with chronic liver disease. The goal is to understand if the medication works differently depending on liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Body mass index (BMI) between 18.0 and 40.0 kg/m² (a measure of height-to-weight ratio)
- For those with normal liver function: no significant medical conditions or abnormal blood work; no hepatitis or HIV
- For those with liver disease: diagnosed chronic liver impairment lasting more than 6 months and stable for 30 days before the study
- No major stomach or intestinal surgery that would affect how your body absorbs medications
- No use of certain medications that interact with this drug for 30 days before dosing
- Not participating in another investigational drug study within the past 30 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
This trial tests an inhaled medication called treprostinil palmitil to see if it can slow the decline of lung function in people with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. It's for people whose lung disease is getting worse despite standard care, and it may help preserve their breathing ability.
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
This program provides access to an inhaled medication called treprostinil for people who have pulmonary hypertension (high blood pressure in the lungs) related to interstitial lung disease (a type of lung scarring). The treatment aims to improve symptoms and quality of life.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.